Several spine and orthopedic companies have made progress with acquisitions in the first quarter of 2025. 1. Stryker has ...

NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.

Spinal cord stimulators have grown in popularity over the past several years as patients see benefits in the less-invasive ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 ...

REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...

REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...

Nevro Corp. NVRO reported a loss per share of ... Additionally, in November 2024, Medical Devices: Evidence and Research demonstrated the Nevro1 SI Joint Fusion System’s superior stability ...

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord ...